{"transactions":[{"id":723674,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:45:14.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001722234-26-000002","document":"form4-06292026_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722234/000172223426000002/form4-06292026_080602.xml","form_type":"4"}},{"id":1022159,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-07T16:30:06.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, MannKind Corporation (\"Parent\") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's common stock (\"Common Stock\") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option."}],"balance_after":0,"derivative":{"exercise_price":4.11,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":19750},"source":{"system":"sec-edgar","filing":"0001193125-25-233531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000119312525233531/ownership.xml","form_type":"4"}},{"id":1022158,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-07T16:30:06.000Z","date":"2025-10-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, MannKind Corporation (\"Parent\") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's common stock (\"Common Stock\") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option."}],"balance_after":0,"derivative":{"exercise_price":3.85,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-233531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000119312525233531/ownership.xml","form_type":"4"}},{"id":1098943,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:06.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":25000,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-018518","document":"form4-06302025_050601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722234/000141588925018518/form4-06302025_050601.xml","form_type":"4"}},{"id":1121271,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T17:31:16.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":30000,"derivative":{"exercise_price":3.85,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-082541","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000095017025082541/ownership.xml","form_type":"4"}},{"id":1467920,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-27T21:01:06.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 25, 2025, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":18000,"derivative":{"exercise_price":16.87,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001415889-24-018343","document":"form4-06272024_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722234/000141588924018343/form4-06272024_090603.xml","form_type":"4"}},{"id":1480660,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T17:00:15.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":19750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":19750,"derivative":{"exercise_price":4.11,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":19750},"source":{"system":"sec-edgar","filing":"0000950170-24-073126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000095017024073126/ownership.xml","form_type":"4"}},{"id":1656412,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-06T22:57:39.000Z","date":"2024-02-02","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest and become exercisable on November 2, 2024, and 1/48th of the shares underlying the option shall vest in equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":36000,"derivative":{"exercise_price":17,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-24-002929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722234/000120919124002929/doc4.xml","form_type":"4"}},{"id":1862222,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T16:15:33.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":17300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":17300,"derivative":{"exercise_price":11.71,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":17300},"source":{"system":"sec-edgar","filing":"0000899243-23-014861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924323014861/doc4.xml","form_type":"4"}},{"id":3113409,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T16:18:15.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":6124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":6124,"derivative":{"exercise_price":7.96,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":6124},"source":{"system":"sec-edgar","filing":"0000899243-20-016168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924320016168/doc4.xml","form_type":"4"}},{"id":3208932,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-16T21:15:42.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":15457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in three equal installments on March 16, 2021, 2022 and 2023."}],"balance_after":15457,"derivative":{"exercise_price":16,"expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":15457},"source":{"system":"sec-edgar","filing":"0000899243-20-008492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008492/doc4.xml","form_type":"4"}},{"id":3208931,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T21:15:42.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":1894444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Lundbeckfond Invest A/S"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S.  The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300752},"source":{"system":"sec-edgar","filing":"0000899243-20-008492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008492/doc4.xml","form_type":"4"}},{"id":3208930,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T21:15:42.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5470492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Lundbeckfond Invest A/S"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S.  The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":868467},"source":{"system":"sec-edgar","filing":"0000899243-20-008492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008492/doc4.xml","form_type":"4"}},{"id":3208929,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T21:15:42.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":478749,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Lundbeckfond Invest A/S"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S.  The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":76003},"source":{"system":"sec-edgar","filing":"0000899243-20-008492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008492/doc4.xml","form_type":"4"}},{"id":3208928,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:15:42.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":false,"nature":"By Lundbeckfond Invest A/S"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S.  The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1432722,"source":{"system":"sec-edgar","filing":"0000899243-20-008492","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008492/doc4.xml","form_type":"4"}},{"id":3208927,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:15:42.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":1245222,"ownership":{"direct":false,"nature":"By Lundbeckfond Invest A/S"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is a managing partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest A/S.  The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1245222,"source":{"system":"sec-edgar","filing":"0000899243-20-008492","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008492/doc4.xml","form_type":"4"}},{"id":3482438,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T16:18:35.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":6124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in full upon the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":6124,"derivative":{"exercise_price":3.37,"exercise_date":"2020-06-18","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":6124},"source":{"system":"sec-edgar","filing":"0000899243-19-017642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924319017642/doc4.xml","form_type":"4"}},{"id":3529172,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T21:01:06.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":6849315,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":776544},"source":{"system":"sec-edgar","filing":"0000899243-19-013253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013253/doc4.xml","form_type":"4"}},{"id":3529171,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:01:06.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":375000,"price":10,"value":3750000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1151544,"source":{"system":"sec-edgar","filing":"0000899243-19-013253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013253/doc4.xml","form_type":"4"}},{"id":3529170,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:01:06.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":776544,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by Lundbeckfond Invest A/S. The reporting person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of Lundbeckfond Invest A/S. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":776544,"source":{"system":"sec-edgar","filing":"0000899243-19-013253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319013253/doc4.xml","form_type":"4"}},{"id":3534817,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-08T21:00:20.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":23684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 7, 2019, effective upon the pricing of the Issuer's initial public offering. This option is scheduled to vest as to (i) 50% of the underlying shares on the earlier of (A) the first anniversary of the date of grant and (B) the date of the first annual meeting of stockholders of the Issuer held following the date of grant and (ii) the remaining 50% of the underlying shares on the earlier of (A) the second anniversary of the date of grant and (B) the date of the second annual meeting of stockholders of the Issuer held following the date of grant."}],"balance_after":23684,"derivative":{"exercise_price":10,"expiration_date":"2029-05-06","underlying":"Common Stock","underlying_shares":23684},"source":{"system":"sec-edgar","filing":"0000899243-19-012648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000089924319012648/doc4.xml","form_type":"4"}},{"id":3886091,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-21T18:40:46.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":6124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in full upon the earlier of (i) June 19, 2019, and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":6124,"derivative":{"exercise_price":5.53,"exercise_date":"2019-06-19","expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":6124},"source":{"system":"sec-edgar","filing":"0000899243-18-017636","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924318017636/doc4.xml","form_type":"4"}},{"id":4062897,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-02-13T17:38:03.000Z","date":"2017-11-21","kind":"purchase","acquired":true,"shares":654762,"price":14,"value":9166668.0,"ownership":{"direct":false,"nature":"By: Lundbeckfond Invest A/S"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 21, 2017, the Reporting Person filed a Form 4 which inadvertently excluded the purchase of shares in the Initial Public Offering of the Issuer by Lundbeckfond Invest A/S (\"LIAS\") of 654,762 shares of Common Stock (the \"Purchase\").  This amendment corrects the exclusion of the purchase by LIAS.  The Purchase was reported on a Form 4 filed by LIAS with the U.S. Securities and Exchange Commission on November 21, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by LIAS. The Reporting Person is the Managing Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":3183986,"source":{"system":"sec-edgar","filing":"0000899243-18-003707","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924318003707/doc4a.xml","form_type":"4/A","original_submission_date":"2017-11-21"}},{"id":4154338,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2017-11-21T19:22:56.000Z","date":"2017-11-21","kind":"exercise","acquired":false,"shares":7067945,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Lundbeckfond Invest A/S"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S (\"LIAS\"),  upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":984366},"source":{"system":"sec-edgar","filing":"0000899243-17-027196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027196/doc4.xml","form_type":"4"}},{"id":4154337,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2017-11-21T19:22:56.000Z","date":"2017-11-21","kind":"exercise","acquired":false,"shares":11092383,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Lundbeckfond Invest A/S"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S (\"LIAS\"),  upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1544858},"source":{"system":"sec-edgar","filing":"0000899243-17-027196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027196/doc4.xml","form_type":"4"}},{"id":4154336,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-21T19:22:56.000Z","date":"2017-11-21","kind":"exercise","acquired":true,"shares":984366,"ownership":{"direct":false,"nature":"By: Lundbeckfond Invest A/S"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S (\"LIAS\"),  upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by LIAS.  The Reporting Person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":2529224,"source":{"system":"sec-edgar","filing":"0000899243-17-027196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027196/doc4.xml","form_type":"4"}},{"id":4154335,"issuer":{"id":74456,"kind":"organization","name":"scPharmaceuticals Inc.","symbol":"SCPH"},"owners":[{"id":34731,"kind":"person","name":"Agger Mette Kirstine","position":1,"cik":"0001722234","reported_name":"Agger Mette Kirstine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-21T19:22:56.000Z","date":"2017-11-21","kind":"exercise","acquired":true,"shares":1544858,"ownership":{"direct":false,"nature":"By: Lundbeckfond Invest A/S"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the total number of shares of Common Stock received by Lundbeckfond Invest A/S (\"LIAS\"),  upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are directly held by LIAS.  The Reporting Person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1544858,"source":{"system":"sec-edgar","filing":"0000899243-17-027196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604950/000089924317027196/doc4.xml","form_type":"4"}}]}